Document is current
Any future updates will be listed below
-
Authors
Wallingford, Courtney K.
Mothershaw, Adam https://orcid.org/0000-0002-0056-8187
Primiero, Clare
Clinch, Tenielle https://orcid.org/0009-0000-6122-3062
Dawson, Tamara
Ingold, Nathan
Soyer, H. Peter
Law, Matthew H.
McInerney-Leo, Aideen https://orcid.org/0000-0002-0059-5732
Yanes, Tatiane https://orcid.org/0000-0002-3905-3025
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP2009136)
Department of Health | National Health and Medical Research Council (APP1137127)
Australian Government Research Training Stipend
University of Queensland
University of Queensland, Faculty of Medicine Fellowship
- License Information
-
More Information
Article History
Received: 10 June 2024
Revised: 8 November 2024
Accepted: 15 November 2024
First Online: 29 November 2024
Competing interests
: HPS is a shareholder of MoleMap NZ Limited and Ederm-consult GmbH and undertakes regular teledermatological reporting for both companies. HPS is a medical consultant for Canfield Scientific, Inc; MoleMap Australia Pty Ltd; Blaze Bioscience, Inc; and Revenio Research Oy and is a medical advisor for First Derm. DGB is employed by Color Health, Inc, a company that returns polygenic scores results. All other authors declare no conflicts of interest.
: Ethics and governance approval for study was granted by the Metro South Human Research Ethics Committee: HREC/2021/QMS/69781. Participation in this study was voluntary, and informed consent was obtained via signed consent forms.
